Medsider: Learn from Medtech and Healthtech Founders and CEOs

In this episode of Medsider Radio, we sat down with Harlee Sorkin, CEO of InterShunt Technologies, a startup developing a minimally invasive catheter designed to treat heart failure. By improving blood flow and lessening the heart's workload via a shunt, the company's technology holds promise for easing heart failure symptoms.Harlee is a co-founder of Common Place Holdings, a venture studio that has spun out eight medtech startups, including InterShunt. Before Common Place, Harlee led Traco Labs, a health and nutrition ingredient manufacturer, to a successful exit. He also served as the Clinical Assistant Professor at the University of Illinois at Urbana-Champaign, where he focused on translating research ideas into commercially viable applications. In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Harlee Sorkin.

In this episode of Medsider Radio, we had an insightful discussion with Patrick Anquetil, CEO of Portal Instruments, a company developing a novel needle-free drug delivery system. This cutting-edge technology promises to revolutionize how medications are administered, making the process less invasive, more precise, and more comfortable for patients. Patrick brings over 20 years of experience leading bioengineering companies from concept to commercial success. Before Portal, he co-founded two medtech startups, SynapDx and Aretais. Patrick holds a doctorate in Mechanical Engineering from MIT, and advanced degrees from Harvard Business School, ETH Zurich, and the University of Tokyo. His scientific achievements have been featured in top journals and media outlets such as MIT Technology Review, Wired Magazine, PBS, and CNBC.In this interview, Patrick talks about how he landed on Portal’s business model, how their team condenses timelines across key company functions, and why their diverse set of partners is a golden asset to the company. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Patrick Anquetil.

In this episode of Medsider Radio, we sat down with Tess Cosad, a femtech enthusiast and CEO of Béa Fertility. Béa offers effective, hormone-free, affordable, at-home fertility treatments and ovulation tracking as an alternative to traditional clinic-based offerings. Before Béa, Tess founded Emberson Ventures, a B2B marketing agency, and Hers By Design, a femtech company. She was also the first woman to lead a digital marketing-focused accelerator program in Saudi Arabia.In this interview, Tess delves into the challenges and triumphs of launching a consumer-facing product, the importance of a solid design team, how to be comfortable making decisions with imperfect information, and the lessons she learned about being a CEO while raising funds.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tess Cosad.

In this episode of Medsider Radio, we had an awesome chat with Carla Spina, the pioneering force behind Noa Therapeutics. Carla and her team are developing treatments for inflammatory skin diseases with their innovative multimodal small-molecule therapies.Carla began her academic journey at the University of Calgary in the fields of inorganic and analytical chemistry, and continued with a Ph.D. in Bioinorganic Chemistry at McGill University. After going to BASF in Germany to develop pharmaceutical formulations, Carla returned to Canada and led the development and global commercialization of antimicrobial wound care devices. Later, she also pioneered first-in-class pharmaceuticals for inflammatory and infectious skin diseases. Currently, she spearheads Noa Therapeutics, a Canadian biotech firm that is transforming how immune diseases are treated.In this episode, Carla shares her invaluable experiences on the importance of engaging actively with the startup ecosystem and staying connected with those who are shaping the field. We talk about how building a company is a collaborative venture that requires a strong network of entrepreneurs, investors, and industry experts, and the significance of authentic interaction when reaching out to a variety of potential stakeholders. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We have also introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Carla Spina.

In this episode of Medsider Radio, we had a fascinating discussion with Daniel Powel, CEO of Spark Biomedical, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Daniel Powell.

In this episode of Medsider Radio, we had an enlightening conversation with Ken Mariash, a leading figure in the neuromodulation space and the CEO of Sinaptica Therapeutics, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease. Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division. In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&A transactions, to mastering commercialization and best practices for engaging with investors.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Ken Mariash.

In this episode of Medsider Radio, we had an insightful conversation with Dave Rosa, President and CEO of NeuroOne, a company developing high-definition, minimally invasive neurology devices utilizing unique thin-film electrode technology. Dave brings over three decades of experience in the medical device industry. His career spans several key roles at major firms like C.R. Bard, Boston Scientific, and St. Jude Medical, focusing on marketing, product development, strategy, and commercialization. Dave has several medical device patents to his name, has served on numerous corporate boards, and raised over $200 million in the capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.In this interview, Dave discusses critical strategies to secure initial capital even before early development and regulatory milestones are achieved, how to leverage networks to connect with potential investors; and the importance of assembling a supportive and experienced team, including board members. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dave Rosa.

In this episode of Medsider Radio, we sat down with John Bertrand, the CEO of Digital Diagnostics, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with John Bertrand.

In this episode of Medsider Radio, we had a fun discussion with Nick Delmonico, CEO of Strados Labs, the company developing a wearable stethoscope to remotely capture lung sounds. Nick boasts a dynamic background with an MBA from the Fox School of Business at Temple University and a Bachelor's in Accounting from the University of Delaware. His career includes roles at ECG Management Consultants, PwC, and J.P. Morgan, where he honed his skills in healthcare strategy, commercialization and operations, business planning, and project management.In this interview, Nick talks about how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. He also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Nick Delmonico.

In this episode of Medsider Radio, we had a riveting conversation with Greg Bullington, co-founder and CEO of Magnolia Medical, who is leading a team in the development of Steripath, a revolutionary device that dramatically improves the accuracy of sepsis tests.Greg’s previous expertise includes leadership positions across biotech, healthcare access, and enterprise software. Over the last decade, Greg has shaped every facet of Magnolia's success, from creating their own category and navigating the regulatory landscape with FDA to collaborating with the U.S. Senate for the widespread adoption of Steripath.In this interview, Greg talks about the pivotal role of robust clinical data, why Magnolia is still running studies even after proving their device’s efficacy, and how to use the results to successfully convince different entities of its benefits, such as FDA and other government bodies in public health. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Greg Bullington.

In this episode of Medsider Radio, we had a spirited conversation with Sahil Diwan, CEO of SafKan Health. Sahil's company is developing the OtoSet, the first automated and FDA-cleared ear-cleaning device. With a background in computer science from the University of Oregon, Sahil's entrepreneurial journey began early. He was already coding at the age of 16 and building startups during his college years. Sahil’s venture into medical technology was inspired by his brother Aadil's struggle with impacted earwax.In this interview, we talk about consumer-driven medtech, the power of design, garnering experience from real-world data, focusing on building the business before fundraising, and how OtoSet went viral on social media. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Sahil Diwan.

In this episode of Medsider Radio, we had a riveting chat with David Hochman, founder and CEO of Orchestra BioMed, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers & acquisitions, and many fundraising successes.In this interview he talks about driving successful partnerships, operational excellence in R&D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with David Hochman.

In this episode of Medsider Radio, we sat down with Deanne McCarthy, founder and CEO of Swiftsure Innovations, a company developing a device capable of safely and effectively cleaning the oral cavity of patients on life support. Deanne was a critical care nurse before she decided to make the switch to medtech entrepreneur. With Deanne's commitment to empowering nurses and enhancing patient outcomes, Swiftsure has assembled an adept team and a robust group of advisors that has enabled the company to move incredibly quickly across key functions like product development, regulatory affairs, and commercialization. In this interview, we explore the invaluable role of mentors and connections in Deanne's journey, her insights on accelerator programs, and how her initial lack of startup experience gave her the tenacity to seek out and validate collaborative partners. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Deanne McCarthy.

In this episode of Medsider Radio, we sat down with Cecile Brosset Dubois, CEO of Sonio, a company dedicated to revolutionizing obstetric ultrasound through AI technology. Cecile began her career in 2005 at Capgemini, later advancing to Bain & Company. Her strategic insights as Head of Strategy at FSI - Fonds Stratégique d'Investissement - and her pivotal roles at Bpifrance set the stage for Cecile's entrepreneurial journey. At Kamet Ventures, she fully embraced the startup world before eventually co-founding Sonio. In this interview, we touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Cecile Brosset.

In this episode of Medsider Radio, we had a chat with Tyler Melton, the co-founder and CEO of Corveus Medical, a Houston-based startup on a mission to redefine heart failure treatment. Tyler previously worked at Accenture, consulting for top-tier pharmaceutical companies, and at the J&J Center for Device Innovation, where he honed his skills in strategic planning and financial modeling. He then joined the Texas Medical Center Biodesign Program, where he uncovered his current mission: to treat heart failure with targeted nerve ablation. In this interview, Tyler shares how using off-the-shelf products for early prototypes saved him both time and money and how accelerator programs provided the networking boost his startup needed to tackle the demanding PMA regulatory pathway. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tyler Melton.

In this episode of Medsider Radio, we sat down with Angus McLachlan, CEO of Liberate Medical, a company pioneering a non-invasive neuromuscular electrical stimulator to prevent muscle weakening in patients who rely on a ventilator to breathe.Angus has a rich academic and professional history that intersects engineering and healthcare. Originating from Scotland, Angus began his academic journey in mechanical engineering at the University of Glasgow. This laid the foundation for his PhD research focused on electrical muscle stimulation for spinal cord injuries. His innovative work gained the attention of Apellis Pharma, leading to a collaboration that propelled the launch of his own company, Liberate Medical. In this interview, we talk about Angus’s do-it-yourself philosophy, how a deep understanding of the technology you’re developing gives you leverage across multiple functions, and the nuances of pitching to investors. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Angus McLachlan.

In this episode of Medsider Radio, we sat down with Kelly Roman, co-founder and CEO of Fisher Wallace, a company spearheading the development of wearable brain stimulation technology aimed at providing relief from depression, anxiety, and insomnia. Kelly is a Harvard graduate with an English major who took an unconventional path to medtech inspired by his experience co-authoring the graphic novel adaptation of Sun Tzu's "The Art of War." He took a career leap from literature and marketing to pioneer a novel approach to the treatment of mental health. In this interview, we delve into what Kelly's learned on his journey, touching on the value of unconventional thinking, the importance of making mental health treatments more accessible and less stigmatized, and the potential of decentralized clinical trials. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Kelly Roman.

In this episode of Medsider Radio, we had a chat with Dr. Alberto Rodriguez-Navarro, CEO of Levita Magnetics, a startup aiming to make surgical procedures as minimally invasive as possible with its advanced magnetic technology. Dr. Rodriguez-Navarro is not only a skilled surgeon but a medtech visionary with multiple patents to his name. Discover Alberto's journey spanning his childhood fascination with using magnets to clean the inside of his turtle tank to leveraging this concept into a cutting-edge magnetic surgery platform. In this interview, Dr. Rodriguez-Navarro discusses what to consider when starting a new business, how to hone your framework when transitioning from the clinic, and early-stage strategies to ease the road to FDA approval. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Rodriguez-Navarro.

In this episode of Medsider Radio, we sat down with Bill Colone, the CEO and Chairman of SinglePass, a company developing an electrocautery device for deep tissue biopsies.Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Bill Colone.

In this episode of Medsider Radio, we sat down with Shyam Natarajan, founder and CEO of Avenda Health, which utilizes artificial intelligence and cutting-edge imaging to improve the diagnosis and treatment of prostate cancer.After getting his PhD in Biomedical Engineering from UCLA, Shyam worked as a postdoctoral scholar in UCLA's Department of Surgery, focusing on minimally invasive surgical interventions. He also managed the UCLA Business of Science Center, spearheading initiatives to guide students toward non-academic career paths. With experiences like founding UCLA Innovation Week and the Inventathon, he is committed to pushing the boundaries of medical technology. At Avenda Health, Shyam is now leading the charge in revolutionizing prostate cancer care. In this interview, we talk about what it really takes to understand the market need for your product or service, how prototypes can be incredibly helpful in convincing relevant parties, how Shyam approaches fundraising, and what to expect from medtech in the future given current technological advancements in growing fields like AI. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Shyam Natarajan.

In this episode of Medsider Radio, we sat down with Dr. David Albert, founder of AliveCor, which is pioneering the standard for personal ECG devices that extend beyond hardware and encompass services and partnerships to offer comprehensive personal cardiovascular solutions.Dr. Albert is a multifaceted individual — a physician, scientist, inventor, serial entrepreneur, YouTube sensation, and even an adventurous surfer. His academic journey led him from Duke University, where he completed both engineering and medical graduate studies, back to his roots at the University of Oklahoma. He already had several licensed inventions when he decided to stake it all on a new cardiovascular device. The gamble led him to found AliveCor, now a frontrunner in personal electrocardiograms (ECGs) under the renowned Kardia brand. In this interview, we take a tour down the lanes of innovation, prototyping, fundraising, and why sometimes you have to ditch the white coat to take your ideas from the lab to the real world.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Albert.

In this episode of Medsider Radio, we sat down with Parag Gad, who founded SpineX to turn cutting-edge science into life-changing devices. The FDA has granted Breakthrough Device Designation for two of SpineX's non-invasive products aimed at improving the lives of adults with neurogenic bladder conditions and children with cerebral palsy.Parag understands both sides of the coin — the research-intensive academic world and the rigorous standards of healthcare regulation. With SpineX, he's marrying the two, aiming for a transformation in spinal healthcare. The company has raised $3.6 million in equity financing and has also secured non-dilutive funding from government agencies. With ongoing multicenter clinical trials and plans for future enrollment, Parag is steering SpineX toward a new frontier in bioelectric medicine.In this interview, Parag delves into the intricate journey of transitioning from academia to entrepreneurship, securing non-traditional funding, and the role of regulatory milestones in building a reputable healthcare brand.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Parag Gad.

In this episode of Medsider Radio, we sat down with Kirsten Carroll, CEO of Kandu Health, and a medtech veteran specializing in neurovascular disorders with nearly 25 years of experience in the field. Kirsten holds a degree in biomedical engineering and dual master's degrees in business and public health. She has held strategic roles at industry leaders like Boston Scientific and Stryker before joining Imperative Care and co-founding Kandu Health. Her startup focuses on revolutionizing post-stroke care and enhancing the quality of life for stroke survivors through tech-enabled healthcare services.In this interview, Kirsten talks about redefining post-stroke care with a comprehensive set of services to improve the well-being of stroke survivors and, consequently, their care partners. From her unique perspective on innovation to her emphasis on a multi-stakeholder approach, Kirsten shares invaluable lessons on breaking down monumental challenges and fostering a culture of teamwork.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor! In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Kirsten Carroll.

In this episode of Medsider Radio, we sat down with Gabriel Jones, co-founder and CEO of Proprio, who has had a career spanning engineering, law, finance, and philanthropy across the world. Gabriel studied engineering at the University of Washington before furthering his career at Tase Kensetsu, a major civil engineering and manufacturing firm in Japan. He then moved to Wall Street to work on large-scale mergers and acquisitions for high-profile clients like AT&T and Google. After returning to Seattle, Gabriel collaborated with the Bill & Melinda Gates Foundation on global healthcare initiatives. Today, he is the CEO of Proprio, a revolutionary medtech startup aiming to improve surgical precision with AI-powered technology.In this interview, the eclectic Gabriel shares how his background has equipped him with a unique framework for creating a thriving startup ecosystem, tips on capital fundraising, and using public relations to his favor.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter. Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more! We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor! In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Gabriel Jones.

In this episode of Medsider Radio, we pull back the curtain on L.R. Fox, the visionary founder of NEXT Life Sciences. With an ambitious mission to democratize family planning, Fox and his team are on the brink of launching their flagship product, Plan A— a groundbreaking male contraceptive.Before founding NEXT Life Sciences, Fox was already a powerhouse entrepreneur in numerous highly regulated industries ranging from cybersecurity to aerospace, including WhiteFox Defense Technologies, a company that is shaping the future of drone airspace security. With a degree in engineering and as a member of the Forbes' 30 Under 30 list in 2019., Fox is currently leading NEXT’s efforts to introduce Plan A to the market. In this interview, Fox shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.Before we dive into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd much rather read, here's a link to the full interview with L.R. Fox.

In this episode of Medsider Radio, we sat down with Sean Morris, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded Euphrates Vascular, an innovative startup in the field of microvascular obstructions.In this interview, Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.Before we dive into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd much rather read, here's a link to the full interview with Sean Morris.

In this episode of Medsider Radio, we sat down with Dr. Krishan Ramdoo, the CEO and creative mind behind the Tympa platform, an all-in-one ear and hearing health assessment system that has gained global recognition.Dr. Ramdoo is a celebrated international speaker, researcher, and educator with a keen focus on the intersection of medical science and technology. Some of the accolades Dr. Ramdoo and the Tympa team have received include the prestigious Royal Society of Medicine prize for innovation in ENT, the Rowena Ryan prize for research into ENT, and the Hartopp-Dixon ENT award.In this interview, he talks about his journey toward becoming a technology innovator, starting as an ENT physician to eventually developing the Tympa platform. Dr. Ramdoo shares invaluable insights on the importance of patient-centric problem-solving, balancing external feedback with personal vision, and the power of tangible products in converting stakeholders to true believers in your solution.Before we dive into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Dr. Ramdoo if you prefer to read it.

In this episode of Medsider Radio, we sat down with Allison London Brown, CEO of Luminelle, who has over 25 years of experience in the healthcare space and has been involved in nearly every aspect of product development for women's health.From Fortune 50 companies like Johnson & Johnson and GE Healthcare to founding startups, Allison has seen it all. Now, as the CEO and co-founder of Luminelle, she's channeling her decades of knowledge into a revolutionary new device aiming to transform gynecological procedures.In this interview, Allison shares insights on how to best understand your strengths and weaknesses, the potential pitfalls of 'one size fits all' regulatory strategies, and innovative methods to secure capital in a risk-averse economy. Before we dive into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Allison if you prefer reading.

In this episode of Medsider Radio, we sat down with David Narrow, CEO of Sonavex, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances. David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists. Before we dive into the discussion, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with David if you prefer reading.

In this episode of Medsider Radio, we sat down with Shriram Raghunathan, a neuroengineering pioneer and CEO of Noctrix Health.Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Shriram if you prefer reading.

In this episode of Medsider Radio, we sat down with Kate Rumrill, CEO of Ablative Solutions, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Kate if you prefer reading.

In this episode of Medsider Radio, we sat down with Lloyd Diamond, CEO of Pixium Vision a company that is developing a groundbreaking retinal implant system for patients suffering from advanced dry age-related macular degeneration (dry AMD).Lloyd has a rich history of guiding medtech and biotech companies. His career spans decades, continents, and sectors, and he has been actively involved in both European and American markets. His experiences with large strategic firms and promising startups have equipped him with a unique entrepreneurial viewpoint. In this interview, Lloyd shares practical lessons on building a lean and adaptable team, navigating the intricacies of regulatory processes, and succeeding at strategic fundraising. His insights, drawn from hands-on experience, provide actionable advice for startups making their way in the challenging medtech landscape.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Lloyd if you prefer reading.

In this episode of Medsider Radio, we sat down with Craig Davis, CEO of NovaScan, a company revolutionizing cancer diagnostics with a low-cost, single-use device capable of real-time cancer detection and stratification.Craig is a strategist, entrepreneur, and leader with a resume boasting a unique blend of business acumen, investment insight, and technical expertise. In this interview, Craig unveils his journey from being a partner at LaSalle Investments to leading the charge in revolutionizing cancer diagnostics. He delves into the myriad of challenges entrepreneurs face, like fostering efficient early-stage development, designing clinical trials for rapid data collection, and mastering the art of fundraising in an ever-evolving financial landscape. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Craig Davis.

In this episode of Medsider Radio, we sat down with Brett Wingeier, co-founder and CTO of Magnus Medical, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded Halo Neuroscience. In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Brett.

In this episode of Medsider Radio, we sat down with Mara McFadden CEO of Endolumik, developers of an innovative fluorescence-guided esophagogastric calibration system. Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson & Johnson and Philips Healthcare. Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Mara McFadden.

In this episode of Medsider Radio, we sat down with Joe Rafferty CEO of Vesteck, a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Joe Rafferty.

In this episode of Medsider Radio, we sat down with Rob Ball CEO of Shoulder Innovations, a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years. In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Rob Ball.

In this episode of Medsider Radio, we sat down with Tim Blair, CEO of ICHOR, an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Blair.

In this episode of Medsider Radio, we sat down with Dave Kuraguntla, co-founder and CEO of Alio, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dave Kuraguntla.

In this episode of Medsider Radio, we sat down with Joe Landolina, co-founder and CEO of Cresilon, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Joe Landolina.

In this episode of Medsider Radio, we sat down with Will Martin, CEO of IRRAS, a company revolutionizing the treatment of intracranial bleeding.Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Will Martin.

In this episode of Medsider Radio, we sat down with Waqaas Al-Siddiq, CEO of Biotrocity, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Waqaas.

In this episode of Medsider Radio, we sat down with Carol Burns, CEO of Cagent Vascular, a medical device company focused on developing and commercializing an innovative angioplasty balloon called the Serenator.Carol is a seasoned CEO and serial entrepreneur with a passion for cardiovascular devices. Her tireless energy and proven track record have enabled Carol to excel in all phases of medical device development, from early-stage proof of concept to eventual commercialization. Carol thrives in the fast-paced startup world, leveraging her industry relationships and clinical knowledge to identify technologies with the highest potential for success.In this interview, Carol highlights the importance of establishing the right team to lay the proper foundation for your medtech startup. We further discuss how to prioritize essential product features and their clinical applications for future growth, as well as overcoming fundraising challenges through effective networking. She also highlights the importance of listening to study investigators and designing strategic clinical trials to generate valuable data and drive success.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Carol Burns.

In this episode of Medsider Radio, we sat down with Steve Dimmer, CEO of CurvaFix, a medical device company focused on developing innovative solutions for orthopedic procedures. Steve holds a Bachelor of Science in Electrical Engineering from San Diego State University and a Master’s in Business Administration from the University of Washington. He has over 30 years of experience building medtech companies, including multiple start-ups and stints at several large multinationals.In this interview, Steve highlights the importance of mitigating risk and pitching to investors early in the development process. He also provides valuable advice on designing clinical trials that meet specific goals based on his own experiences at CurvaFix. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Steve Dimmer.

In this episode of Medsider Radio, we sat down with Lloyd Mencinger, CEO of Aqua Medical, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Lloyd if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Sam Mazin, CEO of RefleXion, a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy. Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Sam if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Ohad Arazi, CEO of Clarius, a leading provider of high-definition wireless ultrasound systems. With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Ohad if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Meesha Dogan, co-founder and CEO of Cardio Diagnostics.Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Meesha if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Osman Khawar CEO of Diality.After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Osman if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dan Zavorotny, co-founder of NutrisenseBefore co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Dan if you'd rather read the summary instead.